Myosteatosis in Oeso-gastric Cancer: Clinical Impacts
1 other identifier
interventional
50
1 country
1
Brief Summary
The aim of this project is to study the presence of cancer-associated adipocytes in oesogastric cancers and their possible links with myosteatosis. This research project has a retrospective component, the aim of which is to analyse the body component based on imaging in patients with oesogastric neoplasia in order to determine the incidence of myosteatosis and to study the relationship with oncological and prognostic data. The second part of the project is prospective and will collect biological material (skeletal muscle, adipose tissue, tumour, blood) for histological, molecular and genomic analyses and will analyse muscle function in patients with oesogastric cancer. It will address the role of adipocytes in the tumour microenvironment of oesogastric cancer, focusing on their interactions with the observed muscle myosteatosis and prognosis. In the future, it will help to identify signalling pathways, targets and patients who could benefit from appropriate treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started May 2024
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 20, 2024
CompletedStudy Start
First participant enrolled
May 1, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2024
CompletedFirst Posted
Study publicly available on registry
May 17, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
May 31, 2026
ExpectedMay 17, 2024
May 1, 2024
Same day
March 20, 2024
May 13, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Myosteatosis
Muscle fat infiltration measured by analysis of tissue density based on a CT scan in L3 with the help of body component analysis software
Through study completion, an average of 2 years
Secondary Outcomes (4)
Physical functional status 1
Through study completion, an average of 2 years
Physical functional status 2
Through study completion, an average of 2 years
Physical functional status 3
Through study completion, an average of 2 years
Cancer-associated adipocytes
Through study completion, an average of 2 years
Study Arms (2)
Surgical patients
OTHERPatients undergoing surgery
Non surgical patients
OTHERPatients not undergoing surgery
Interventions
Determination of myosteatosis by imaging
Eligibility Criteria
You may qualify if:
- Patients with cancer of the oesophagus, oeso-gastric junction or stomach
- Treatment and estimated survival of more than 3 months
- Signed informed consent
- \> 18 years of age
You may not qualify if:
- Neuromuscular or orthopedic pathology
- Cognitive disorders
- Psychiatric disorders
- Inability to communicate in French or English
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Cliniques universitaires Saint-Luc
Brussels, 1200, Belgium
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Yannick Deswysen, MD
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 20, 2024
First Posted
May 17, 2024
Study Start
May 1, 2024
Primary Completion
May 1, 2024
Study Completion (Estimated)
May 31, 2026
Last Updated
May 17, 2024
Record last verified: 2024-05
Data Sharing
- IPD Sharing
- Will not share